FDA Approves Pfizer's Biosimilar, ABRILADA for Multiple Inflammatory Conditions
November 18, 2019
November 18, 2019
NEW YORK, Nov. 18 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA(TM) (adalimumab-afzb), as a biosimilar to Humira(R) (adalimumab),/1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis./2 . . .
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA(TM) (adalimumab-afzb), as a biosimilar to Humira(R) (adalimumab),/1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis./2 . . .